Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: J Pathol. 2019 Apr 22;248(3):260–265. doi: 10.1002/path.5261

Figure 3.

Figure 3

Genomic comparison of inverted urothelial papilloma (IUP), urothelial papilloma (UP), non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC). (A) Frequency of TP53, RB1, TERT promoter, FGFR3, KRAS and HRAS alterations in IUP (n=11), UP (n=11), MSK-NMIBC n=105 [12], MSK-MIBC (n=117; unpublished data) and TCGA-MIBC n=412 [11]. * indicates p value <0.05. (B) Frequency of oncogenic alterations in molecular pathways in IUP (n=11), UP (n=11), MSK-NMIBC n=105 [12], MSK-MIBC (n=117; unpublished data) and TCGA-MIBC n=412 [11] cohort. * indicates p value <0.05. (C) OncoPrint showing molecular pathways in IUP (n=11), UP (n=11) and cases with oncogenic HRAS/KRAS mutations in MSK-NMIBC (n=12), MSK-MIBC (n=3) and TCGA-MIBC (n=30).